Skip to content

Enovis ENOV Prevention & Recovery — Net Sales

Other segment segments

Reconstructive
$317.13M+10.8%

Similar metrics at other companies

Avanos Medical logo
AVNSTotal Pain Management and Recovery — Net Sales
$56.3M+0.2%
Avanos Medical logo
AVNSSurgical pain and recovery — Net Sales
$21.8M-11.0%
Avanos Medical logo
AVNSPM&R — Net Sales
$56.3M+0.2%
Baxter International logo
BAXMedical Products & Therapies — Net Sales
$1.29B+1.8%
TFX
TFXSurgical — Net revenues
$106.79M+12.4%
Abbott logo
ABTMedical Devices — Net Sales
$5.54B+13.2%

Other financials

Income statement

See full
Revenue$589.2M+5.4%
Gross profit$365.5M+10.0%
Operating income$6.5M+114%
Net income-$8.8M+84.3%
EPS (diluted)-$0.15+84.7%

Balance sheet

See full
Cash & equivalents$33.1M-13.9%
Total debt$1.4B-3.1%
Total equity$1.5B-43.6%
Total assets$3.8B-21.4%

Cash flow

See full
Operating cash flow$24.0M+1,601%
CapEx$52.8M+22.1%
Free cash flow-$28.9M+35.7%

Valuation

See full
Market cap$1.23B-28.4%
Enterprise value$2.55B-17.1%
P/S0.5×-0.3×

Profitability

See full
Gross margin60.5%+4.0pp
Operating margin-47%+18.6pp
Net margin-49.9%+24.1pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-55.5%-1,722pp
Debt / equity0.9×+0.4×
Current ratio-0.5×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Enovis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enovis's prevention & recovery — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enovis's prevention & recovery — net sales?
Enovis (ENOV) reported prevention & recovery — net sales of $272.02M in Q1 2026.
What does prevention & recovery — net sales mean?
The total revenue generated from the sale of medical devices and rehabilitation products within the Prevention & Recovery segment, after accounting for returns, allowances, and discounts. This is the primary indicator of the segment's market demand and commercial success in the medical technology space.